A Phase 3 interventional study of Pembrolizumab and Gemcitabine in Biliary Tract Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing pembrolizumab in Cholangiocarcinoma — 3 open to participants now, 5 under way, 1 of them phase 3. pembrolizumab · Cholangiocarcinoma.
Among the 12 studies testing pembrolizumab in Cholangiocarcinoma, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 8th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →3 of the 12 studies testing pembrolizumab in Cholangiocarcinoma are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 4
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 91 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 5 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
3 of the studies testing pembrolizumab in Cholangiocarcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06178445Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEfficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer | 2026-12 |
| NCT02628067Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | 2027-05-04 |
| NCT05967182M.D. Anderson Cancer CenterA Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing pembrolizumab in Cholangiocarcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).
The China extension study will include participants previously enrolled in China in the global study for MK-3475-966 (NCT04003636) plus those enrolled during the China extension enrollment period. A total of approximately 158 Chinese participants will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stop the initial course of pembrolizumab with stable disease (SD) or better but progress after discontinuation will initiate a second course of pembrolizumab 200 mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with gemcitabine can be stopped at any time in first or second course due to toxicity or disease progression.
Biological: Pembrolizumab · Drug: Gemcitabine · Drug: Cisplatin
Participants receive placebo to pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.
Drug: Gemcitabine · Drug: Cisplatin · Drug: Placebo
Pembrolizumab by intravenous (IV) infusion
Also known as: MK-3475
Gemcitabine by IV infusion
Also known as: Gemzar
Cisplatin by IV infusion
Also known as: Platinol®, Platinol®-AQ
Placebo to pembrolizumab by IV infusion
Overall Survival (OS)
Overall survival was defined as the time from randomization to death due to any cause. Per protocol the final reported outcome for OS did not include any sensitivity or supportive analysis.
Time frame: Up to approximately 29 months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR
PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.
Time frame: Up to approximately 29 months
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.
Time frame: Up to approximately 29 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.
Time frame: Up to approximately 29 months
Number of Participants Who Experienced One or More Adverse Events (AEs)
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs was reported.
Time frame: Up to approximately 29 months
Number of Participants Who Discontinued Study Intervention Due to an AE
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who discontinued study intervention (includes any study medication given during the study) due to an AE were reported.
Time frame: Up to approximately 29 months
Per protocol, response or progression during the second course treatment was not counted towards efficacy outcome measures, and adverse events during the second course treatment were not counted towards safety outcome measures.
| Milestone | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Started | 75 | 83 |
| Treated | 74 | 82 |
| Participants who received second course of pembrolizumab | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 75 | 83 |
| Withdrew: Death | 65 | 77 |
| Withdrew: Sponsor decision | 10 | 6 |
Overall survival was defined as the time from randomization to death due to any cause. Per protocol the final reported outcome for OS did not include any sensitivity or supportive analysis.
| Months | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 14.1 (10.4 to 17.7) | 9.9 (8.6 to 13.0) |
PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.
| Months | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR | 5.6 (3.2 to 7.4) | 5.7 (4.4 to 6.9) |
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.
| Percentage of participants | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR | 36.0 (25.2 to 47.9) | 28.9 (19.5 to 39.9) |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.
| Months | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR | 10.2 (5.4 to NA) | 5.7 (4.2 to 14.0) |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs was reported.
| Participants | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events (AEs) | 73 | 82 |
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who discontinued study intervention (includes any study medication given during the study) due to an AE were reported.
| Participants | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy |
|---|---|---|
| Number of Participants Who Discontinued Study Intervention Due to an AE | 18 | 14 |
Collected over Up to approximately 56 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| First Course: Arm A: Pembrolizumab + Chemotherapy | 65/75 (86.7%) | 29/74 (39.2%) | 73/74 (98.6%) |
| First Course: Arm B: Placebo + Chemotherapy | 77/83 (92.8%) | 29/82 (35.4%) | 82/82 (100%) |
| Second Course: Arm A: Pembrolizumab + Chemotherapy | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | First Course: Arm A: Pembrolizumab + Chemotherapy | First Course: Arm B: Placebo + Chemotherapy | Second Course: Arm A: Pembrolizumab + Chemotherapy |
|---|---|---|---|
| Platelet count decreasedInvestigations | 9/74 | 7/82 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 5/74 | 3/82 | 0/1 |
| Neutrophil count decreasedInvestigations | 5/74 | 2/82 | 0/1 |
| Jaundice cholestaticHepatobiliary disorders | 1/74 | 5/82 | 0/1 |
| Biliary tract infectionInfections and infestations | 4/74 | 4/82 | 0/1 |
| White blood cell count decreasedInvestigations | 3/74 | 3/82 | 0/1 |
| MyelosuppressionBlood and lymphatic system disorders | 2/74 | 1/82 | 0/1 |
| Febrile infectionInfections and infestations | 2/74 | 1/82 | 0/1 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/74 | 0/82 | 0/1 |
| MyocarditisCardiac disorders | 1/74 | 2/82 | 0/1 |
| Event | First Course: Arm A: Pembrolizumab + Chemotherapy | First Course: Arm B: Placebo + Chemotherapy | Second Course: Arm A: Pembrolizumab + Chemotherapy |
|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 19/74 | 30/82 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 59/74 | 65/82 | 0/1 |
| White blood cell count decreasedInvestigations | 58/74 | 62/82 | 0/1 |
| Neutrophil count decreasedInvestigations | 55/74 | 58/82 | 0/1 |
| Platelet count decreasedInvestigations | 47/74 | 46/82 | 0/1 |
| NauseaGastrointestinal disorders | 38/74 | 35/82 | 0/1 |
| VomitingGastrointestinal disorders | 31/74 | 37/82 | 0/1 |
| Alanine aminotransferase increasedInvestigations | 16/74 | 28/82 | 0/1 |
| Decreased appetiteMetabolism and nutrition disorders | 20/74 | 28/82 | 0/1 |
| ConstipationGastrointestinal disorders | 15/74 | 20/82 | 0/1 |
All Chinese participants who were randomized to the global study (NCT04003636) or to the extension portion.
| Age, Continuous(Years) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Mean | 59.5 ± 8.3 | 58.6 ± 9.5 | 59.0 ± 8.9 |
| Sex: Female, Male(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Female | 39 | 36 | 75 |
| Male | 36 | 47 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 75 | 83 | 158 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 75 | 83 | 158 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Geographic Region(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Asia | 75 | 83 | 158 |
| Disease Status(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Locally Advanced | 12 | 14 | 26 |
| Metastatic | 63 | 69 | 132 |
| Site of Origin(Participants) | Arm A: Pembrolizumab + Chemotherapy | Arm B: Placebo + Chemotherapy | Total |
|---|---|---|---|
| Gallbladder | 19 | 12 | 31 |
| Intrahepatic | 45 | 60 | 105 |
| Extrahepatic | 11 | 11 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2020 to primary completion in Dec 2022, 29 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab